A Hard Look at Third-Party External Supply Networks - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Hard Look at Third-Party External Supply Networks
The complexity of third-party external supply networks requires new ways to manage them.


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 7, Issue 5


Gregg Brandyberry
I had dinner recently with an old and very insightful Big Pharma colleague of mine and after speaking together, he revealed an important concern. "Gregg, I'm worried," he said. "I think the complexities of our current global supply chain outweigh our capability to control the network," he continued. He was talking about his company's third-party external supply network.

It's a scary thought, the idea of being too big and complex to adequately control an organization's supply chain properly. But as my colleague and I discussed this in more detail, I definitely understood why he felt that way. For the past 20 years and especially the past decade, the industry has watched the evolution into "gigantic pharmaceutical drug-makers," such as Johnson & Johnson, Pfizer, Roche, Merck & Co, Novartis GlaxoSmithKline, and sanofi-aventis, all $40-billion-plus annual revenue behemoths.

These global giants are the results of mergers, acquisitions, and myriad comarketing, in-licensing, and other growth strategies to make up for the disappointing failures of traditional research and development. The resulting manufacturing "mash-ups" have created third-party external supply networks that are difficult to manage because of the overall number of contract manufacturing organization (CMOs) involved, long-term contracts (some with substandard organizations), contracts with no provisions for ongoing cost reductions and a host of other nuances that result in the buying organization having a higher risk profile than desired.

Now, there is no doubt that making changes to the network can be difficult and expensive due to product registrations and other regulatory hurdles on a country-by-country basis. But if a company is willing to play a longer game, with a forward vision, it is possible for it to optimize its third-party external network to reduce all types of supply risk and ensure the ability to manufacture products cost effectively.

There is a new methodology, called collaborative optimization, which I've had the chance to become familiar with through my work as senior advisor for A.T. Kearney Procurement and Analytic Solutions. The methodology has its roots in optimizing transportation logistics. It's been successfully used in many direct and indirect categories of spend as diverse as packaging, chemicals and temporary labor and also to simultaneously optimize multiple categories of spend used in sequential manufacturing processes. It was designed for complex categories of spend when the complexity comes from many specifications, many potential suppliers with a multitude of capabilities, and regional or global manufacturing and distribution needs.

Collaborative optimization has three important components. First, it is establishes deep analytics in the cost makeup of a product or service through the creation of an extremely detailed cost breakdown. Second, it gives all suppliers the ability to quote in multiple ways, including creatively (i.e., quote on parts of the business that plays to an individual suppliers strengths and/or provide new ways to meet the requirements that are more cost efficient). This function is called expressive bidding and makes ups the "guts" of a very new type of request for quotation that has an abundance of cost-rich information and cost-reduction ideas.

The real differentiator with collaborative optimization is the ability to use combinatorial optimization through an embedded combinatorial analyzer that allows for scenario comparisons to be rapidly generated. These comparisons determine the most desirable outcome based on what a corporation must have. This requirement might be the lowest total price or the best total cost when certain constraints are added. This method overcomes many of the limitations in today's procurement approaches by fostering creativity into the quotation process and handling large amounts of data in a fast and efficient way, thereby enabling the buying entity to determine the best solution for its specific needs. What I like the best about collaborative optimization is that it does not pit supplier against supplier the way traditional procurement practice often does. Instead, it identifies the best way forward that is beneficial to buyers and suppliers alike.

So, how could this methodology be applied to a third-party external network? To start, a corporation would need to decide it wants to fix the "mess" (a word used by the late, great systems thinker, Russell L. Ackoff, PhD, to describe most current state situations). The company also would need to recognize that the fix might take 5 to 10 years to fully implement. For a corporation that was willing to play the long game using collaborative optimization, the benefits would be substantial. One benefit is that it allows a company to identify where new contract-manufacturing opportunities should be sourced. It also allows a company to understand where existing contract manufacturing should be sourced and if there is a financial or risk-based business case to support working through regulatory and/or contractual barriers. This method also ensures that the best CMO network had been identified to reduce all types of risk and provide real cost competitiveness.

When a company thinks about its the third-party external supply network, a crucial question to consider is whether the company is using a CMO's total capabilities across its total product requirements on a global basis. From my experience, which includes more than 30 years in procurement, the supply chain, and related operations, including 10 years as vice-president of procurement of global systems and operations at GlaxoSmithKline, I'm fairly confident that the answer would be "no." And that reply is really no fault of an individual or an organization. It goes back to what my colleague and I were discussing: the complexities of what an organization is dealing with are greater than its ability to control unless there is a commitment to develop a long-term vision and a willingness to adapt and use different approaches in managing a third-party external supply network. Collaborative optimization offers the potential for annual incremental savings and potentially a lower overall risk profile.

The key factor for effective supplier management is that once a company has established what its end-state third-party external network should look like and what suppliers should constitute that network, it is imperative that there is an ongoing collaborative environment and culture in place that ensures that future supply partners are always incented to improve and innovate. This evaluation may make an organization take a hard look at the skills or lack of skills that it has in place to support third-party external manufacturing relationships. My guess is that there are some gaps in relationship management. Identifying and filling those gaps is a first crucial step in improving supplier management.

To gain additional insight from Gregg Brandyberry and other experts, view an educational webcast, "How to Optimize CMC Development and Manufacturing," at the multimedia section at http://PharmTech.com/.

Gregg Brandyberry is CEO of Wildfire Commerce, and senior advisor for A.T. Kearney Procurement and Analytic Solutions, tel. 215-327-5739,
.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
8%
Protecting the supply chain
40%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here